Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer

被引：0
|
作者：
Mattos, Bruna RaphaeliSilva [1 ]
Cesca, Marcelle Goldner [1 ]
Leite, Luciana de Moura [1 ]
Tavares, Monique Celeste [1 ]
Silva, Sinara Figueiredo [1 ]
Pirolli, Rafaela [1 ]
Fogassa, Camilla AlbinaZanco [1 ]
Silva, Erick Figueiredo [1 ]
Rocha, Francisca Giselle [1 ]
Loose, Simone Klug [1 ]
Campos, Fernando AugustoBatista [1 ]
Sanches, Solange Moraes [1 ]
de Lima, Vladmir ClaudioCordeiro [1 ]
Ponde, Noam Falbel [1 ]
机构：
[1] AC Camargo Canc Ctr, Sao Paulo, Brazil
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS4-40
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Response to neoadjuvant chemotherapy in HER2 non-overexpressing breast cancer subtypes
    Ilie, S. M.
    Desmoulins, I.
    Hennequin, A.
    Coureche-Guillaume, K.
    Arnould, L.
    Nathalie, B.
    Bertaut, A.
    Ladoire, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [42] Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
    Shi, Yue
    Lu, Heng
    Zhang, Yiqi
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 206 (02) : 387 - 395
  • [43] Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer
    Wang, Yihong
    Singh, Kamaljeet
    Dizon, Don
    Graves, Teresa
    Amin, Ali
    Yakirevich, Evgeny
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (03) : 667 - 676
  • [44] Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer
    Yihong Wang
    Kamaljeet Singh
    Don Dizon
    Teresa Graves
    Ali Amin
    Evgeny Yakirevich
    Breast Cancer Research and Treatment, 2021, 186 : 667 - 676
  • [45] Gain of HER2 Amplification in Patients with HR+/HER2-and Triple Negative Early Breast Cancer Treated with Neoadjuvant Chemotherapy
    Ferraro, Emanuela
    Minmin, Sonya Chew
    Safonov, Anton
    Barrio, Andrea V.
    Modi, Shanu
    Seidman, Andrew D.
    Wen, Hanna Y.
    Brogi, Edi
    Robson, Mark E.
    Dang, Chau T.
    CANCER RESEARCH, 2023, 83 (05)
  • [46] Prognostic factors in nonmetastatic HER2 'low' & HER2 'negative' breast cancer: Single institute experience
    Turkel, A.
    Dogan, M.
    Sertesen, E.
    Karacin, C.
    Irkkan, S. C.
    Ates, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S299 - S300
  • [47] Changes in HER2 status after neoadjuvant treatment of breast cancer
    Skalova, H.
    Dundr, P.
    Povysil, C.
    Pribylova, O.
    Petruzelka, L. B.
    Tvrdik, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2
    Ahuja, Sana
    Khan, Adil Aziz
    Zaheer, Sufian
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 262
  • [49] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
    Wang, Wei
    Zhu, Tingting
    Chen, Hao
    Yao, Yongzhong
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (06) : 1673 - 1681
  • [50] HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2-positive or HER2-negative tumors?
    Landmann, Alessandra
    Farrugia, Daniel J.
    Diego, Emilia
    Bonaventura, Marguerite
    Soran, Atilla
    Johnson, Ronald
    Dabbs, David J.
    Clark, Beth
    Brufsky, Adam
    Davidson, Nancy E.
    Lembersky, Barry C.
    Jankowitz, Rachel Catherine
    Puhalla, Shannon
    Ahrendt, Gretchen M.
    McAuliffe, Priscilla F.
    Bhargava, Rohit
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345